Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 13.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,360 shares of the biopharmaceutical company’s stock after purchasing an additional 5,909 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Alexion Pharmaceuticals were worth $6,784,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Jennison Associates LLC grew its stake in Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after acquiring an additional 4,682,336 shares during the last quarter. BlackRock Inc. grew its stake in Alexion Pharmaceuticals by 7.0% in the 2nd quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock valued at $2,424,428,000 after acquiring an additional 1,298,185 shares during the last quarter. Third Point LLC acquired a new stake in Alexion Pharmaceuticals in the 2nd quarter valued at about $152,088,000. Janus Henderson Group PLC grew its stake in Alexion Pharmaceuticals by 1,697.6% in the 2nd quarter. Janus Henderson Group PLC now owns 1,145,918 shares of the biopharmaceutical company’s stock valued at $139,424,000 after acquiring an additional 1,082,171 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its stake in Alexion Pharmaceuticals by 42.2% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 3,219,961 shares of the biopharmaceutical company’s stock valued at $391,773,000 after acquiring an additional 955,578 shares during the last quarter. Institutional investors and hedge funds own 95.80% of the company’s stock.
In related news, EVP Julie O’neill sold 4,375 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total value of $636,300.00. Following the transaction, the executive vice president now owns 26,092 shares in the company, valued at $3,794,820.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the transaction, the director now owns 5,480 shares in the company, valued at approximately $799,038.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,330 shares of company stock worth $774,851. Insiders own 4.35% of the company’s stock.
Alexion Pharmaceuticals, Inc. (ALXN) opened at $108.61 on Monday. The firm has a market cap of $24,260.00, a PE ratio of 22.21, a PEG ratio of 1.18 and a beta of 1.22. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $149.34. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.12. The business had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company’s revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.23 EPS. research analysts anticipate that Alexion Pharmaceuticals, Inc. will post 4.81 earnings per share for the current year.
ALXN has been the topic of a number of research reports. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Royal Bank Of Canada increased their price objective on shares of Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. Piper Jaffray Companies reissued an “overweight” rating and issued a $170.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd. TheStreet cut shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, November 10th. Finally, Stifel Nicolaus lowered their price objective on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research note on Tuesday, October 24th. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $154.01.
TRADEMARK VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://transcriptdaily.com/2017/11/27/alexion-pharmaceuticals-inc-alxn-shares-bought-by-zurcher-kantonalbank-zurich-cantonalbank.html.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.